PG
PTCT icon

PEAK6 Group’s PTC Therapeutics PTCT Stock Holding History

PEAK6 Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$5.96M Sell
176,600
-53,100
-23% -$1.66M 0.03% 690
2018
Q1 		$6.22M Buy
229,700
+229,600
+229,600% +$5.82M 0.03% 691
2017
Q4 		$2K Buy
+100
New +$1.69K ﹤0.01% 3997
2015
Q3 		– Sell
-7,700
Closed -$371K – 5504
2015
Q2 		$371K Buy
7,700
+2,100
+38% +$123K ﹤0.01% 3088
2015
Q1 		$341K Buy
+5,600
New +$342K ﹤0.01% 2943

Other funds holding PTCT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PEAK6 Group's PTCT Position: Q2 2018 in Review

PEAK6 Group reduced its PTC Therapeutics (PTCT) stake by 58% in Q2 2018, selling an estimated $1M and leaving 23,286 shares worth $785K. The position accounts for ﹤0.01% of the portfolio, ranked #2183.

PEAK6 Group first reported a position in PTCT in Q1 2015 and has held it in 4 quarters since. The position peaked at $1.5M in Q1 2018. 166 funds tracked by Wall St. Rank hold PTCT as of Q2 2018.

  • PEAK6 Group held 23,286 shares of PTC Therapeutics worth $785K as of Q2 2018.
  • PEAK6 Group sold 32,157 PTC Therapeutics shares in Q2 2018, an estimated $1M.
  • PTC Therapeutics made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #2183 holding.
  • PEAK6 Group first reported a position in PTC Therapeutics in Q1 2015 and has held it in 4 quarters since.
  • PEAK6 Group's PTC Therapeutics position peaked at $1.5M in Q1 2018.
  • 166 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.